ClinicalTrials.gg
CompletedNCT05779241Updated Oct 24, 2024

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

A Phase 3 interventional study of LYN-005 and Risperidone in Schizophrenia and Schizoaffective Disorder, sponsored by Lyndra Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Lyndra Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
582nd of 1,319
83 · median 66
Started
2023
with 39 others
Phase 3
196 of 1,465
19 open now
Registered
1,309th of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 582nd largest by enrollment of the 1,319 interventional ones that give a count, is one of 40 that started in 2023, is one of 196 in phase 3, and was the 1,309th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

Lyndra Therapeutics, Inc. is developing LYN-005, a long-acting oral (LAO) capsule (LYNX™ dosage form) of risperidone. This pivotal study (LYN-005-C-301) will evaluate the PK as well as safety and tolerability of multiple administrations of the LYN-005 formulation at two dose levels.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged ≥18 and ≤64 years.
  2. Current diagnosis of schizophrenia or schizoaffective disorder according to (DSM-5) criteria as confirmed by the Mini International Neuropsychiatric Interview for Psychotic Disorder Studies (MINI) version 7.0.2.
  3. The following psychiatric criteria are to be used to determine participant eligibility:

    1. Duration of diagnosis of schizophrenia or schizoaffective disorder of ≥2 years.
    2. Outpatient; not hospitalized for worsening of schizophrenia within the last 6 months (partial hospitalization for social management within this time period is acceptable).
    3. Medically stable over the last month and psychiatrically stable without significant symptom exacerbation over the last 3 months.
  4. Stabilized on an oral antipsychotic medication (single agent) for a minimum of 6 weeks at the time of Screening.
  5. On a stable dosage of all permitted non-antipsychotic medications (except for medication to be used on an as-needed basis) for at least 1 month before the Screening visit and for the duration of the study.
  6. Clinical Global Impression-Severity (CGI-S) score of ≤4 (moderately ill) at screening.
  7. PANSS score of ≤80 points at screening.
  8. (BMI) ≥18 kg/m2 and ≤38 kg/m2.
  9. Able to read and understand study procedures and provide written before the initiation of any protocol-specific procedures.
  10. Willing to comply with all protocol-specified procedures and availability for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Participants with known esophageal or gastrointestinal (GI) disease, including but not limited to:

    1. Known strictures such as esophageal web, pyloric stenosis, or small intestinal stricture, or participants with high risk of stricture, eg, Crohn's disease.
    2. Diagnosis of a condition known to elevate or lower gastric pH, eg, achlorhydria or hypochlorhydria.
    3. Prior varices or small or large bowel obstructions.
    4. Prior abdominal or upper gastrointestinal surgery (prior uncomplicated laparoscopic procedures including appendectomy or colectomy are permitted).
    5. History of dysphagia or aspiration in the last 5 years.
    6. History of an esophageal motility disorder or undergoing treatment for a gastric motility disorder.
    7. Significant history of diarrhea or constipation within 3 months of Screening. For constipation, 2 or more of the following in the preceding 12 months (the episodes need not be consecutive): i. Straining >1/4 of defecations; ii. Lumpy or hard stools >1/4 of defecations; iii. Sensation of incomplete evacuation >1/4 of defecations; iv. Sensation of anorectal obstruction/blockage >1/4 of defecations; v .Manual maneuvers to facilitate >1/4 of defecations (e.g., digital evacuation, support of the pelvic floor); vi.\<3 defecations per week; vii. Loose stools are not present, and there are insufficient criteria for irritable bowel syndrome.
    8. Multiple episodes of abdominal pain within 3 months of Screening.
    9. Moderate or severe dysmenorrhea or menorrhagia (with use of pain medication) within 3 months of Screening.
    10. History of moderate to severe Acid Reflux Disease or a score of ≥2 on the Acid Reflux Severity Scale (ARSS) [2] , indicating moderate to severe symptoms.
  2. PILL-5 questionnaire score of 5 or greater.
  3. Medical history or current diagnoses indicating the presence of any of the below conditions:

    1. Presence of an uncontrolled, unstable, clinically significant medical condition that could put the participant at risk because of participation in the study, interfere with the participant's ability to participate in the study or influence the interpretation of safety or PK evaluations.
    2. History of a major cardiovascular event (myocardial infarction, cardiac surgery or revascularization, unstable angina, stroke, or ) or a hospitalization for heart failure with 6 months of Screening.
    3. Any clinically significant illness, medical or surgical procedure or trauma within 4 weeks of Screening.
    4. Known status, including individuals who have undergone organ transplantation, on immunosuppression for an immune mediated disease, or are positive for (HIV).
    5. Positive test for active or C at Screening. Participants with successfully treated hepatitis B infection which has been resolved for greater than 1 year or successfully treated infection will not be excluded.
    6. Donated more than 250 mL of blood within 30 days of Screening.
    7. Have difficulties with venipuncture/cannulation, including difficulty accessing veins for blood sampling and/or history of coagulopathy or endocarditis.
    8. Current diagnosis of major depressive episode, panic disorder, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder on the MINI 7.0.2 or in the judgment of the Investigator. (Note that individuals with depression secondary to schizoaffective disorder are eligible).
    9. Suicidal ideation associated with actual intent and a method or plan in the past 6 months, as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS; ie, "Yes" answers on items 4 or 5) at Screening or Day -7, or having made a suicide attempt within the last 2 years.
    10. Known or suspected (non -febrile) seizure disorder.
    11. History of neuroleptic malignant syndrome.
    12. Current or history of clinically significant tardive dyskinesia.
    13. Known or suspected diagnosis of intellectual disability or organic brain disorder or other diagnosis that is primarily responsible for current symptoms and functional impairment.
    14. Medically non-adherent in the management of their schizophrenia/schizoaffective disorder.
  4. Use of the below medications/treatments in the 2 weeks before enrollment, including:

    1. Proton pump inhibitors or H2 blockers.
    2. Prokinetic agents.
    3. Medications that may interfere with the absorption, metabolism, or excretion of risperidone, e.g.: i. Drugs metabolized via cytochrome P450 3A4 () pathway, such as macrolide antibiotics and azole antifungals); ii. Moderate or strong CYP3A4 p-glycoprotein enzyme inducers and inhibitors (carbamazepine, phenytoin, rifampicin, phenobarbital, itraconazole, verapamil); iii. Moderate or strong cytochrome P450 2D6 (CYP2D6) inhibitors (e.g., fluoxetine, fluoxetine combinations, paroxetine, or quinidine).
    4. Concomitant medications, natural remedies, supplements, or vitamins which are associated with changes to gastric motility or pH. Use of antacids is permissible, except within 2 hours of dosing with LYN-005.
    5. Use of more than one antidepressant; or if on just one, a change in dose within 6 weeks of Screening.
    6. Depot antipsychotic use within 9 months of Screening.
    7. Electroconvulsive therapy within 3 months of Screening.
  5. Participants with clinically significant abnormal safety (e.g. physical examination, vital sign) or safety laboratory assessments, specifically:

    1. Presence of a clinically significant abnormal laboratory result on blood or urine safety tests at Screening.
    2. Anemia ( below lower limit of normal reference range) at Screening.
    3. (ALT), aspartate aminotransferase (AST) ≥3.0 × (ULN), or total ≥1.5 × ULN.
    4. Moderate or severe renal insufficiency at Screening ( \<60 mL/min, as determined using the formula).
    5. Heart rate \<50 beats per minute (bpm).
    6. Systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg at Screening.
    7. Orthostatic hypotension (or history of orthostatic hypotension), defined as a decrease of ≥20 millimeters of mercury (mmHg) in systolic pressure or a decrease of ≥10 mm Hg in diastolic pressure after 2 minutes of standing, or if standing causes signs and symptoms, at Screening or Day -7
    8. (HbA1c) ≥7.0%.
    9. Positive fecal occult blood test.
    10. Clinically significant prolactin elevation (≥200 ng/mL for females; ≥100 ng/mL for males).
  6. Participants with the below specified patterns of substance use :

    1. Fulfillment of the DSM-5 criteria for moderate or severe substance use disorder (excluding nicotine and caffeine) within 6 months of Screening.
    2. History of alcohol consumption exceeding moderate use; in males exceeding 21 units per week and in females exceeding 14 units per week (1 unit = 360 ml beer, 25 mL of 40% spirit or 125 mL wine) over the past month. Participants are not permitted to consume alcohol during the inpatient stay nor 12 hours before any clinic visit while outpatient.
    3. Positive ethanol breathalyzer at Screening or Day -7.
    4. Positive urine drug screen for substances of abuse other than cannabis at Screening or Day -7.
    5. Heavy nicotine use (consumption of >40 cigarettes or >36 mg of nicotine from other sources [eg, vaping products] daily) or daily use of smokeless tobacco.
  7. Participants of who are (hetero) sexually active but unwilling to use acceptable means of through the Safety Follow-up (SFU). For clarity, participants who are at least 1 year are not of reproductive potential. Acceptable means of contraception include:

    1. Participants who have been surgically sterilized (males who have undergone a vasectomy at least 3 months before LYN-005 and have a documented negative sperm count test; females who have undergone tubal ligation or hysterectomy).
    2. Females of reproductive potential: diaphragm, injectable, oral/patch contraceptives for a minimum of 6 weeks, contraceptive sponge, implant, or intrauterine device in use before enrollment.
    3. Males: condom in combination with any of the above means of contraception.
    4. All participants: abstinence may be an acceptable means of contraception as long as the individual consents to initiate immediate use of double barrier protection for the duration of the study should (hetero) sexual intercourse occur.
  8. Participants who are nursing or who have positive or indeterminate pregnancy tests at either Screening (serum test) or Day -7 (urine test).
  9. Use of any experimental agent within 1 month or 5 half-lives of Screening, whichever is longer.
  10. Participants who are employees or immediate family members of employees of the site, Sponsor or study-related vendors.
  11. History of a serious allergic or reaction to risperidone or LYN-005 (refer to Investigator's Brochure).
  12. Participants with history of X-ray, computed tomography scan or angiogram of the abdomen within one year of Screening.
  13. Participants with CYP2D6 poor or underdetermined metabolizer status based on genetic testing.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    LYN-005 Containing 15-mg Risperidone

    During the run-in period (Day -7 to Day -1), participants receive Risperdal® (IR risperidone) daily. During the treatment period, participants receive 5 weekly doses of LYN-005 15 mg (Days 1, 8, 15, 22, and 29) and Risperdal 1 mg from Day 1 to Day 7.

    Drug: LYN-005 · Drug: Risperidone

  • Experimental
    LYN-005 Containing 45-mg Risperidone

    During the run-in period (Day -7 to Day -1), participants receive Risperdal® (IR risperidone) daily. During the treatment period participants receive 5 weekly doses of LYN-005 45 mg (Days 1, 8, 15, 22, and 29) and Risperdal 3 mg from Day 1 to Day 7.

    Drug: LYN-005 · Drug: Risperidone

Interventions

  • DrugLYN-005

    Risperidone long-acting oral capsule

  • Risperidone immediate release (IR) oral tablets

    Also known as: Risperdal

06

What researchers measure

Primary outcomes

  1. Minimum Observed Concentration (Cmin) at Week 1

    Time frame: up to Day 36

  2. Minimum Observed Concentration (Cmin) at Week 5

    Time frame: up to Day 36

  3. Maximal Observed Concentration (Cmax) at Week 5

    Time frame: up to Day 36

  4. Average Concentration Over the Dosing Interval (Cavg) at Week 5

    Time frame: up to Day 36

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs) From Week 1 to Week 5

    Time frame: Week 1 to Week 5

  2. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) to Week 5

    The total score range for the PANSS is 30-210. Higher scores indicate more severe symptoms.

    Time frame: Baseline, up to Week 5

07

Study locations

5 sites
  • CenExel CNS
    Garden Grove, California 92845, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Nov 2023, 6 months.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 6 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2023
First posted
Mar 22, 2023
StartActual
Apr 13, 2023
Primary completionActual
Nov 3, 2023
CompletionActual
Dec 1, 2023
Results delay requested
Oct 4, 2024
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05779241
Lead sponsor
Lyndra Inc.
Responsible party
Sponsor
First posted
Mar 22, 2023
Start date
Apr 13, 2023
Primary completion
Nov 3, 2023
Completion
Dec 1, 2023
Last update
Oct 24, 2024

Study contacts

Richard Scranton, MD, MPH
principal investigator · Lyndra Therapeutics INC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion